18655-49-7

Upstream product

• 24654-56-6 3-(3-chloro-phenyl)-acrylamide 
• 587-04-2 m-Chlorobenzaldehyde 
• 21640-48-2 3-chlorohydrocinnamic acid 
• 22991-03-3 3-(3-chlorophenyl)propanol 
• 1866-38-2 m-Chlorocinnamic acid 
• 24654-56-6 3-(3-chloro-phenyl)-acrylamide 
• 16799-05-6 2-(3-chlorophenyl)ethyl bromide 
• 5182-44-5 2-(3-chlorophenyl)ethanol 
• 21640-47-1 3‐(3‐chlorophenyl)propanenitrile 

Relevant academic research and scientific papers

2-IMIDAZOLYL-PYRIMIDINE SCAFFOLDS AS POTENT AND SELECTIVE INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE

Imidazolyl-pyrimidine and related compounds, as can utilize heme-iron coordination in the selective inhibition of neuronal nitric oxide synthase.

Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase

Selective inhibition of neuronal nitric oxide synthase (nNOS) is an important therapeutic approach to target neurodegenerative disorders. However, the majority of the nNOS inhibitors developed are arginine mimetics and, therefore, suffer from poor bioavai

Methods of treatment using an EP2 selective receptor agonist

The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP2 selective receptor agonist.

Method for treating glaucoma

Methods of using prostaglandin agonists for the reduction of intraocular pressure, and accordingly glaucoma.

Prostaglandin agonists and their use to treat bone disorders

This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

Calcium receptor-active compounds

The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders by modulating inorganic ion receptor activity. Preferably, the compound can mimic or block the effect of extracellular Ca2+on a calcium receptor.

Prevention of loss and restoration of bone mass by certain prostaglandin agonists

Prostaglandin agonists of formula (I), in which, for example, A is a sulphonyl or acyl group, B is N or CH, M contains a ring and K and Q are linking groups, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits useful for the treatment of bone disorders including osteoporosis. STR1

Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT3 serotonin receptors

Arylpiperazines are nonselective agents that bind at 5-HT3 serotonin receptors with moderate to high affinity, whereas 1-phenylbiguanide is a low- affinity but more selective 5-HT3 agonist. In an attempt to enhance the affinity of th